Cone snails, a group of predatory marine gastropods found mostly in tropical waters, produce some of the most pharmacologically potent compounds on Earth. Their venom, a cocktail of small peptides called conotoxins, has already yielded one FDA-approved painkiller and is now fueling research into faster-acting insulin, new analgesics that sidestep the opioid crisis, and precision tools for studying the nervous system. The journey from a slow-moving sea snail’s hunting weapon to a hospital pharmacy is one of the more unlikely stories in modern drug development, and it is far from over.
How a Snail Catches a Fish
Cone snails are not what most people picture when they think of venomous predators. They are small, shell-dwelling animals that crawl along reefs and sandy bottoms. Yet some species hunt fish, an astonishing feat for an animal with no legs, no speed, and no jaws. The trick is chemical. A fish-hunting cone snail extends a hollow, harpoon-like tooth made of chitin, hydraulically propels it into a passing fish, and injects venom through the hollow shaft in a fraction of a second. The harpoon also acts as a tether, keeping the prey attached while neurotoxins take effect.1Current Biology. The high speed radular prey strike of a fish-hunting cone snail Within moments, the fish is paralyzed by a burst of neuroexcitatory peptides and swallowed whole.
Not all cone snails hunt fish. Roughly 700 described species span a spectrum of prey preferences. Some target worms, others hunt other snails, and a smaller subset specializes in fish. Each ecological niche comes with a distinct venom profile. Even within a single species, the cocktail can change depending on the situation: researchers have found that some cone snails deploy one mixture for catching prey and a different subset of toxins for defending against predators.2PubMed Central. Predatory and Defensive Strategies in Cone Snails How the snail selects which venom to inject in which context remains an open question.
Fish-hunting species have evolved particularly sophisticated strategies. Researchers have identified distinct groups of venom components, called cabals, that work together to modify prey behavior in specific ways.3PubMed Central. Prey-Capture Strategies of Fish-Hunting Cone Snails: Behavior, Neurobiology and Evolution One cabal might cause instant rigid paralysis for a hook-and-line style attack, while another might sedate a school of small fish so the snail can engulf them in its distensible mouth like a net. In the net-hunting species Conus tulipa, a venom peptide called ρ-TIA that blocks adrenergic receptors plays a key role in suppressing the fish’s escape reflex.4PubMed Central. The α1-adrenoceptor inhibitor ρ-TIA facilitates net hunting in piscivorous Conus tulipa
Why the Venom Is So Diverse
Each cone snail species produces somewhere in the range of 100 to 200 distinct venom peptides, and those peptides vary enormously from species to species. Across the entire genus, the total count of unique conotoxins is estimated to be in the tens of thousands, possibly between 50,000 and 100,000. Most are short peptides, typically 12 to 30 amino acids long, held in rigid three-dimensional shapes by two or three internal disulfide bonds.5PubMed Central. Efficient oxidative folding of conotoxins and the radiation of venomous cone snails
This staggering diversity arose through a cycle of gene duplication and rapid natural selection. Conotoxin genes duplicate and then diverge at a pace faster than almost any other known protein-coding genes. Positive selection pressure drives the duplicated genes to evolve new functions quickly, generating a wide toolkit of peptides that target different receptors in different prey species. This molecular arms race is considered a major driver of the evolutionary success of the genus itself.6PubMed. Molecular genetics of ecological diversification: duplication and rapid evolution of toxin genes of the venomous gastropod Conus
The diversity is amplified further by heavy post-translational modification. After a conotoxin peptide is translated from its gene, the cell’s machinery can chemically alter individual amino acids in ways that change how the finished molecule behaves. One conotoxin isolated from Conus textile, for example, showed bromination, hydroxylation, and glycosylation on top of its disulfide bonds, an unusual degree of chemical decoration that appeared to help it target calcium channels at nerve terminals.7PubMed. A conotoxin from Conus textile with unusual posttranslational modifications reduces presynaptic Ca2+ influx Another modification, gamma-carboxyglutamate, has been shown to help conotoxins fold correctly into their active shapes.5PubMed Central. Efficient oxidative folding of conotoxins and the radiation of venomous cone snails
What Conotoxins Do to the Nervous System
The reason conotoxins are so interesting to pharmacologists is their extreme selectivity. Rather than acting as broad-spectrum poisons, individual conotoxins tend to lock onto very specific subtypes of ion channels and receptors in the nervous system. Cone snail venom collectively hits voltage-gated sodium, potassium, and calcium channels as well as ligand-gated channels like nicotinic acetylcholine receptors.8PubMed Central. Conotoxins targeting nicotinic acetylcholine receptors: an overview But each individual peptide typically targets just one channel subtype, sometimes with an affinity that synthetic chemistry has struggled to match.
Researchers classify conotoxins into pharmacological families based on these targets. Omega-conotoxins block voltage-gated calcium channels, making them potent disruptors of neurotransmitter release at synapses.9PubMed Central. Omega-conotoxins as experimental tools and therapeutics in pain management Mu-conotoxins plug the pore of voltage-gated sodium channels, blocking the electrical impulses that nerve and muscle cells use to communicate.10PubMed Central. Voltage-Gated Sodium Channel Inhibition by µ-Conotoxins Alpha-conotoxins antagonize nicotinic acetylcholine receptors with high specificity for individual receptor subtypes.11PubMed. Solving the alpha-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists And kappa-conotoxins, delta-conotoxins, and several other families round out a toolbox that, between them, can intervene at nearly every step in neuromuscular signaling.12PubMed. Pharmacological Classes of Conus Peptides Targeted to Calcium, Sodium, and Potassium Channels
This selectivity is what makes conotoxins medically valuable. Most conventional drugs that target ion channels affect multiple subtypes at once, which creates side effects. A conotoxin that blocks just the N-type calcium channel, for instance, can interrupt pain signaling without shutting down the heart’s calcium-dependent rhythm. That specificity is hard to engineer from scratch, but evolution has been refining it in cone snail venom for millions of years.
Ziconotide and the Proof of Concept
The clearest example of a conotoxin making it to the clinic is ziconotide, marketed as Prialt. It is a synthetic version of omega-conotoxin MVIIA, originally isolated from the venom of the fish-hunting species Conus magus. The FDA approved it in 2004 for severe chronic pain, making it a rare success story in non-opioid analgesic development, a field littered with failed candidates.13PubMed Central. Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways
Ziconotide works by selectively blocking N-type voltage-gated calcium channels in the spinal cord. These channels normally allow calcium ions to flood into nerve terminals, triggering the release of neurotransmitters that relay pain signals upward to the brain. By plugging those channels, ziconotide interrupts the pain signal at the spinal level without engaging opioid receptors at all.14PubMed Central. Ziconotide: a review of its pharmacology and use in the treatment of pain The drug cannot cross the blood-brain barrier from the bloodstream, so it must be delivered directly into the spinal fluid through an implanted pump, a procedure called intrathecal administration. That limitation restricts its use to patients with severe, treatment-resistant pain who have exhausted other options.
Despite the delivery hurdle, ziconotide has important advantages. Unlike opioids such as morphine, it does not produce tolerance. In a long-term study called PRIZM, patients on ziconotide maintained stable doses or even reduced them over 12 months, while opioid users typically need escalating doses to achieve the same relief. It also lacks the respiratory depression risk that makes opioid overdose so dangerous. When side effects do occur, such as dizziness, nausea, or confusion, they tend to resolve within days to two weeks once the dose is reduced or stopped.15PubMed Central. Can Ziconotide Be Used to Replace Opioids? Exploratory Clinical Experience in 5 Patients Treated in the Pain Unit Gradual dose titration helps patients tolerate higher effective doses without triggering those side effects.
Seeing How Conotoxins Fit Their Targets
Understanding why conotoxins are so selective has advanced rapidly with structural biology. In 2019, researchers published a cryo-electron microscopy structure of a human sodium channel, Nav1.2, bound to the mu-conotoxin KIIIA at a resolution of 3.0 angstroms. The structure revealed that the 16-amino-acid peptide nestles into the extracellular mouth of the channel pore, with a single lysine residue positioned right at the entrance to the selectivity filter, the narrow region that normally lets sodium ions through.16PubMed. Molecular basis for pore blockade of human Na(+) channel Na(v)1.2 by the μ-conotoxin KIIIA Seeing this interaction at atomic detail helps explain why the peptide blocks one sodium channel subtype but not others: the fit depends on subtle shape differences in the channel’s outer vestibule.
This kind of structural insight is not just academic. Drug designers can use it to tweak conotoxin scaffolds, swapping in amino acids that shift selectivity toward a desired channel subtype or improve binding strength. It is a major reason the field has moved beyond simply testing crude venom and toward rational peptide engineering.
The Oral Delivery Problem
The fact that ziconotide requires a spinal pump highlights a central challenge for conotoxin-based drugs: peptides are fragile. The digestive system breaks them down, the bloodstream degrades them quickly, and they struggle to cross biological barriers. If you swallowed a conotoxin pill, your stomach acid and enzymes would shred it before it reached the bloodstream.
One strategy researchers are pursuing is backbone cyclization, where the two ends of a linear peptide are chemically joined to form a continuous loop. This eliminates the exposed ends that digestive enzymes recognize, making the peptide harder to chew apart. The approach has shown real promise in the lab. A cyclized version of alpha-conotoxin TxIB, for instance, retained about half its integrity after 48 hours in human serum, while the linear version degraded much faster.17PubMed Central. Effects of Cyclization on Activity and Stability of α-Conotoxin TxIB Similar results have been seen with cyclized alpha-conotoxin TxID, which remained roughly half intact in serum after 24 hours.18Gazi University Journal of Science. Head-to-Tail Cyclization of α-Conotoxin TxID Leads to Enhanced Stability in Serum
In-test-tube stability gains, however, do not always translate to the living body. A study of cVc1.1, a backbone-cyclized analgesic conotoxin that had shown impressive stability in lab conditions and was orally active in animal models, found that when the peptide was actually tracked inside an animal, its half-life and oral bioavailability were surprisingly similar to the linear version.19Medicine in Drug Discovery. Effects of backbone cyclization on the pharmacokinetics and drug efficiency of the orally active analgesic conotoxin cVc1.1 The gap between serum stability and real pharmacokinetics is a sobering reminder that making a conotoxin survive the gut is only part of the puzzle. Getting enough of it into the bloodstream and to the right tissue at the right concentration remains a major engineering hurdle.
Manufacturing Challenges
Even setting aside delivery, producing conotoxins at pharmaceutical scale is tricky. These peptides rely on their disulfide bonds to hold their three-dimensional shape, and if those bonds form incorrectly during synthesis, the result is a misfolded, inactive mess. Ziconotide, for example, is a 25-amino-acid peptide with three disulfide bonds, meaning there are 15 possible ways those bonds could pair up, but only one arrangement gives the active molecule. Developing efficient synthesis required systematic optimization of both the solid-phase peptide assembly and the subsequent aqueous-phase folding step, ultimately achieving high purity and the correct three-dimensional structure confirmed by spectroscopy.20Peptide Science. Ziconotide (ω‐conotoxin MVIIA)—Efficient solid‐phase synthesis of a linear precursor peptide and its strategic native folding
Researchers have explored several strategies to improve folding yields, including regioselective chemistry that forces particular cysteine pairs to bond first, modified oxidation conditions, and even recombinant expression in living cells.21PubMed. Folding of conotoxins: formation of the native disulfide bridges during chemical synthesis and biosynthesis of Conus peptides More recently, computational approaches have entered the picture. A 2025 study used AlphaFold 3, a protein structure prediction tool, combined with energy calculations to predict the order in which disulfide bonds form during folding, potentially guiding synthetic chemists toward better conditions for producing the correct form.22PubMed. Dissecting oxidative folding of conotoxins using 3D structures of cysteine mutants predicted by AlphaFold 3 The ability to computationally predict folding steps, rather than testing dozens of conditions by trial and error, could meaningfully speed up development of new conotoxin-derived drugs.
Discovering New Conotoxins Faster
With potentially tens of thousands of conotoxins across hundreds of species, the bottleneck is no longer finding new peptides but characterizing what they actually do. Traditional discovery was slow: researchers would milk a snail, separate the venom into fractions, test each fraction on a cell or tissue, and then work backward to identify the active molecule. That approach works, but it takes years per peptide.
The field has shifted toward what is called venomics, a combination of genomic sequencing of venom gland genes, mass spectrometry-based proteomics to identify which peptides are actually expressed, and pharmacological screening to figure out what the peptides bind to. This approach has already expanded the number of known conotoxin sequences by orders of magnitude, though the vast majority of newly identified sequences remain pharmacologically uncharacterized.23PubMed Central. Venomics-Accelerated Cone Snail Venom Peptide Discovery The main challenge now is integrating the flood of sequence data with functional data, connecting the dots between what genes are present, which peptides show up in the actual venom, and what those peptides do to mammalian targets. That integration problem is essentially a big-data challenge, and it’s one the field is actively building infrastructure to address.
Weaponized Insulin and Its Medical Echoes
Perhaps the most surprising compound found in cone snail venom is insulin. Two fish-hunting species, Conus geographus and Conus tulipa, produce specialized insulin molecules as major venom components. When these insulins are injected into the water around a school of small fish, they trigger a rapid drop in blood sugar, sending the fish into hypoglycemic shock and making them sluggish enough to engulf.24PubMed Central. Specialized insulin is used for chemical warfare by fish-hunting cone snails It is biological warfare by metabolic sabotage.
The snail’s insulin turns out to have a feature that human insulin researchers have been chasing for decades: it is naturally monomeric. Human insulin forms clumps of six molecules in storage and needs to dissociate into single molecules before it can bind to receptors and lower blood sugar. That dissociation step is the main reason injected insulin takes time to start working. The cone snail version, Con-Ins G1, skips clustering entirely because its molecular chain is shorter. It binds human insulin receptors, though with substantially reduced potency compared to native human insulin. Using the structural lessons from Con-Ins G1, researchers engineered what they called “mini-Ins,” the shortest bioactive human insulin analog discovered at the time of the study. In lab and animal experiments, mini-Ins showed biological potency comparable to both native insulin and the rapid-acting commercial insulin Humalog.25The FASEB Journal. Mini‐Ins: a Monomeric Human Insulin Inspired From Cone Snail Venom Peptides A monomeric insulin that works as fast as current rapid-acting formulations but is simpler in structure could eventually lead to faster-acting diabetes treatments, though clinical development is still in early stages.
When Humans Are the Prey
While researchers study cone snails for drug leads, the animals remain genuinely dangerous to handle. Human envenomations typically happen when someone picks up a live cone snail, attracted by its often beautiful shell, and the snail stings defensively through a net or glove. No antivenom exists for cone snail stings.
Symptoms can range from mild to fatal depending on the species and the amount of venom injected. Local effects at the sting site include sharp burning or stinging pain, numbness, swelling, and skin discoloration. Systemic symptoms can escalate to spreading numbness around the lips and mouth, difficulty swallowing and speaking, blurred or double vision, muscle paralysis, and in the worst cases, respiratory failure and cardiac arrest. Death, when it occurs, is usually from respiratory failure, typically 40 minutes to 5 hours after the sting.26Asian Pacific Journal of Tropical Medicine. Faunal data and envenomation emergency first aid of cone snails (Conus spp.) in Qeshm Island, the Persian Gulf
First aid follows a few critical principles. Getting the victim out of the water is the first priority to prevent drowning if paralysis sets in. A pressure-immobilization bandage, the same technique used for certain snake bites, is recommended to slow venom spread. The victim may be paralyzed but fully conscious, so talking to them and keeping them calm matters. Mouth-to-mouth ventilation and CPR should be ready in case respiratory muscles fail. The things not to do are equally important: do not incise or suction the wound, do not apply heat, cold, vinegar, or alcohol, do not elevate the stung limb, and do not give painkillers, since their side effects can complicate an already dangerous situation. There is also no point in trying to catch the snail for identification, since no species-specific antivenom exists and the attempt wastes time and risks a second sting.26Asian Pacific Journal of Tropical Medicine. Faunal data and envenomation emergency first aid of cone snails (Conus spp.) in Qeshm Island, the Persian Gulf
The species most associated with human fatalities is Conus geographus, the same net-hunting fish specialist whose venom insulin researchers now study for diabetes leads. The irony is pointed: the same molecular sophistication that makes cone snail venom lethal is precisely what makes it medically useful. Every peptide that can shut down a human nerve channel with frightening efficiency is also a candidate for a drug that shuts down exactly the right nerve channel, in exactly the right tissue, at exactly the right dose.